CMS has assigned a permanent reimbursement J-code for Dexycu through the Healthcare Common Procedure Coding System, EyePoint Pharmaceuticals announced in a press release.
Dexycu (dexamethasone intraocular suspension) 9%, the first FDA-approved, single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation, will have the code J1095, which will become effective Jan. 1, 2019. The code will replace the C-code C9034 that was previously issued for Dexycu.
“The issuance of a specific and permanent J-code for Dexycu is another key milestone for the company
Uncategorized